Search details
1.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 25(5): 614-625, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38697155
2.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Breast Cancer Res
; 26(1): 20, 2024 01 31.
Article
in English
| MEDLINE | ID: mdl-38297352
3.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 401(10390): 1773-1785, 2023 05 27.
Article
in English
| MEDLINE | ID: mdl-37086745
4.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36858723
5.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825192
6.
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
N Engl J Med
; 382(7): 597-609, 2020 02 13.
Article
in English
| MEDLINE | ID: mdl-31825569
7.
Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy.
Ann Surg Oncol
; 30(1): 100-106, 2023 Jan.
Article
in English
| MEDLINE | ID: mdl-35941343
8.
CDK4/6 inhibition triggers anti-tumour immunity.
Nature
; 548(7668): 471-475, 2017 08 24.
Article
in English
| MEDLINE | ID: mdl-28813415
9.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature
; 529(7586): 413-417, 2016 Jan 21.
Article
in English
| MEDLINE | ID: mdl-26735014
10.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
; 189(2): 411-423, 2021 Sep.
Article
in English
| MEDLINE | ID: mdl-34302589
11.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Article
in English
| MEDLINE | ID: mdl-33591468
12.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34120223
13.
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
Future Oncol
; 17(34): 4665-4676, 2021 Dec.
Article
in English
| MEDLINE | ID: mdl-34636255
14.
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
Breast Cancer Res
; 22(1): 131, 2020 11 30.
Article
in English
| MEDLINE | ID: mdl-33256829
15.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Article
in English
| MEDLINE | ID: mdl-33138866
16.
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Breast Cancer Res Treat
; 180(3): 597-609, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-32100144
17.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Article
in English
| MEDLINE | ID: mdl-31047803
18.
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors.
Int J Cancer
; 145(7): 1798-1808, 2019 10 01.
Article
in English
| MEDLINE | ID: mdl-30680712
19.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat
; 178(1): 121-133, 2019 Nov.
Article
in English
| MEDLINE | ID: mdl-31368034
20.
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).
Breast Cancer Res Treat
; 176(2): 303-310, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-31004299